Investigation on Electrospun and Solvent-Casted PCL-PLGA Blends Scaffolds Embedded with Induced Pluripotent Stem Cells for Tissue Engineering
Pharmaceutics · 06.12.2023 · 15 (12) · 2736
DOI: 10.3390/pharmaceutics15122736 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 06.12.2023. Verfasst von Mariella Rosalia und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The design, production, and characterisation of tissue-engineered scaffolds made of polylactic-co-glycolic acid (PLGA), polycaprolactone (PCL) and their blends obtained through electrospinning (ES) or solvent casting/particulate leaching (SC) manufacturing techniques are presented here. The polymer blend composition was chosen to always obtain a prevalence of one of the two polymers, in order to investigate the contribution of the less concentrated polymer on the scaffolds’ properties. Physical–chemical characterization of ES scaffolds demonstrated that tailoring of fibre diameter and Young modulus (YM) was possible by controlling PCL concentration in PLGA-based blends, increasing the fibre diameter from 0.6 to 1.0 µm and reducing the YM from about 22 to 9 MPa. SC scaffolds showed a “bubble-like” topography, caused by the porogen spherical particles, which is responsible for decreasing the contact angles from about 110° in ES scaffolds to about 74° in SC specimens. Nevertheless, due to phase separation within the blend, solvent-casted samples displayed less reproducible properties. Furthermore, ES samples were characterised by 10-fold higher water uptake than SC scaffolds. The scaffolds suitability as iPSCs culturing support was evaluated using XTT assay, and pluripotency and integrin gene expression were investigated using RT-PCR and RT-qPCR. Thanks to their higher wettability and appropriate YM, SC scaffolds seemed to be superior in ensuring high cell viability over 5 days, whereas the ability to maintain iPSCs pluripotency status was found to be similar for ES and SC scaffolds.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Drug Sciences, University of Pavia, Viale Taramelli 12, 27100 Pavia, Italy.
- Consorzio Interuniversitario per lo Sviluppo dei Sistemi a Grande Interfase (C.S.G.I.), Department of Chemistry, Physical Chemistry Section, University of Pavia, Via Taramelli 10, 27100 Pavia, Italy.
- Translational Cardiomyology Laboratory, Head Unit of Stem Cell and Developmental Biology (SCDB), Head Department of Development and Regeneration, KU Leuven, ON4 Herestraat 49, Box 804, 3000 Leuven, Belgium.
ORCID-Profile: Mariella Rosalia, Rossella Dorati, Giovanna Bruni, Ida Genta, Silvia Pisani, Maurilio Sampaolesi, Bice Conti
Zitieren
APA
Rosalia, M., Giacomini, M., Tottoli, E. M., Dorati, R., Bruni, G., Genta, I., Chiesa, E., Pisani, S., Sampaolesi, M., & Conti, B. (2023). Investigation on Electrospun and Solvent-Casted PCL-PLGA Blends Scaffolds Embedded with Induced Pluripotent Stem Cells for Tissue Engineering. Pharmaceutics, 15(12), 2736. https://doi.org/10.3390/pharmaceutics15122736
Vancouver
Rosalia M, Giacomini M, Tottoli EM, Dorati R, Bruni G, Genta I, et al. Investigation on Electrospun and Solvent-Casted PCL-PLGA Blends Scaffolds Embedded with Induced Pluripotent Stem Cells for Tissue Engineering. Pharmaceutics. 2023;15(12):2736. doi:10.3390/pharmaceutics15122736
BibTeX
@article{Rosalia2023,
author = {Rosalia, Mariella and Giacomini, Martina and Tottoli, Erika Maria and Dorati, Rossella and Bruni, Giovanna and Genta, Ida and Chiesa, Enrica and Pisani, Silvia and Sampaolesi, Maurilio and Conti, Bice},
title = {Investigation on Electrospun and Solvent-Casted PCL-PLGA Blends Scaffolds Embedded with Induced Pluripotent Stem Cells for Tissue Engineering},
journal = {Pharmaceutics},
year = {2023},
volume = {15},
number = {12},
pages = {2736},
doi = {10.3390/pharmaceutics15122736}
}
EUVIMED